药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

UCB的Vimpat在威尔士获得NHS绿灯

2018-03-08 MedSci MedSci原创

UCBVimpat
关注

全威尔士药品战略小组已批准NHS资助UCB的Vimpat用于癫痫患儿。去年9月，基于成年人的外推数据和儿童收集的安全/药代动力学数据，欧洲监管机构批准了对Vimpat (lacosamide)的儿科使用，作为对4岁及以上的患者进行局部发作(焦点)癫痫发作的辅助治疗。在威尔士，大约有10- 29%的儿科癫痫病患者使用目前可用的抗癫痫药物来控制癫痫发作，这强调了新的治疗方案的必要性。"AWMSG对NH

全威尔士药品战略小组已批准NHS资助UCB的Vimpat用于癫痫患儿。去年9月，基于成年人的外推数据和儿童收集的安全/药代动力学数据，欧洲监管机构批准了对Vimpat (lacosamide)的儿科使用，作为对4岁及以上的患者进行局部发作(焦点)癫痫发作的辅助治疗。在威尔士，大约有10- 29%的儿科癫痫病患者使用目前可用的抗癫痫药物来控制癫痫发作，这强调了新的治疗方案的必要性。"AWMSG对NHS威尔士4至16岁儿童接受Vimpat是儿科癫痫治疗的重要一步，这种状况可能给儿童及其家庭带来重大挑战，"杰夫o沃伦（Jeff Wren）说， 他是UCB神经病患者联盟副主席。苏格兰的儿科患者在上个月接受了来自苏格兰药物协会的绿灯后，也得到了NHS的许可。Vimpat于2008年9月首次在欧盟上市，作为治疗部分发作性癫痫的辅助治疗，伴有或不伴有癫痫的成年人和青少年（16-18岁）的继发性综合征。原文出处：www.pharmatimes.com/news/ucbs_vimpat_gets_nhs_green_light_in_wales_1226338此文系梅斯医学（MedSci)原创整理编译，

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18074, encryptionId=3063180e442, topicName=UCB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41d27846369, createdName=ms9474365431325850, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515261, encodeId=f0c1151526135, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294441, encodeId=374b2944415a, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:05 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294302, encodeId=69be2943028b, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Mar 08 23:00:48 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294279, encodeId=5c542942e908, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Mar 08 21:48:52 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-10 ms9474365431325850

    #UCB#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18074, encryptionId=3063180e442, topicName=UCB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41d27846369, createdName=ms9474365431325850, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515261, encodeId=f0c1151526135, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294441, encodeId=374b2944415a, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:05 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294302, encodeId=69be2943028b, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Mar 08 23:00:48 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294279, encodeId=5c542942e908, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Mar 08 21:48:52 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-10 小几洁

    #NHS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18074, encryptionId=3063180e442, topicName=UCB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41d27846369, createdName=ms9474365431325850, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515261, encodeId=f0c1151526135, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294441, encodeId=374b2944415a, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:05 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294302, encodeId=69be2943028b, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Mar 08 23:00:48 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294279, encodeId=5c542942e908, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Mar 08 21:48:52 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-09 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18074, encryptionId=3063180e442, topicName=UCB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41d27846369, createdName=ms9474365431325850, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515261, encodeId=f0c1151526135, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294441, encodeId=374b2944415a, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:05 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294302, encodeId=69be2943028b, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Mar 08 23:00:48 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294279, encodeId=5c542942e908, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Mar 08 21:48:52 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 131****2916

    不错的文章值得推荐

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18074, encryptionId=3063180e442, topicName=UCB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41d27846369, createdName=ms9474365431325850, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515261, encodeId=f0c1151526135, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Mar 10 12:34:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294441, encodeId=374b2944415a, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 09 07:17:05 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294302, encodeId=69be2943028b, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Mar 08 23:00:48 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294279, encodeId=5c542942e908, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Mar 08 21:48:52 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 清风拂面

    谢谢分享学习

    0

相关资讯

UCB抗癫痫药Vimpat获欧盟批准单药治疗部分发作性癫痫，年销售峰值将达到12亿美元

 比利时制药巨头优时比（UCB）抗癫痫药Vimpat（lacosamide，拉科酰胺）近日在欧盟监管方面传来喜讯。欧盟委员会（EC）已批准Vimpat作为一种单药疗法，用于青少年（16-18岁）及成人癫痫患者部分发作性癫痫（partial-onset seizure，POS）的治疗。在欧盟，Vimpat于2008年9月首次获批上市，作为一种辅助药物，用于青少年（16-18岁）和成人癫痫患